Focus: Airway Therapeutics is a public biotechnology company specializing in protein therapeutics for respiratory and airway disorders, headquartered in Marietta, Georgia. The company focuses on rare and orphan lung conditions with limited treatment options.
Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Airway Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Airway Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Airway Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Airway Therapeutics gets NHLBI grant for zelpultide alfa BPD trial - AllSci
Airway Therapeutics gets NHLBI grant for zelpultide alfa BPD trial AllSci
Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa - PR Newswire
Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa PR Newswire
Atlantans Discover New Treatment for Newborns - Atlanta Jewish Times
Atlantans Discover New Treatment for Newborns Atlanta Jewish Times
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub